Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

被引:3
|
作者
Zengin, Zeynep B. [1 ]
Govindarajan, Ameish [1 ]
Salgia, Nicholas [1 ]
Sayegh, Nicolas [2 ]
Tripathi, Nishita [2 ]
Muddasani, Ramya [1 ]
Chehrazi-Raffle, Alex [1 ]
Feng, Matthew [1 ]
Mercier, Benjamin D. [1 ]
Ladbury, Colton [3 ]
Hao, Claire [3 ]
Salgia, Sabrina [1 ]
Chawla, Neal [1 ]
Meza, Luis [1 ]
Malhotra, Jasnoor [1 ]
Dizman, Nazli [1 ]
Hsu, JoAnn [1 ]
V. Castro, Daniela [1 ]
Barragan-Carrillo, Regina [4 ]
Ebrahimi, Hedyeh [1 ]
Philip, Errol J. [5 ]
Chang, Mark [6 ]
Zhang, Jiaming [7 ]
Byron, Sara [7 ]
Lyou, Yung [1 ]
Dorff, Tanya [1 ]
Pal, Sumanta K. [1 ,6 ,7 ,8 ]
Dandapani, Savita [3 ,8 ]
机构
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA
[2] Univ Utah, Huntsman Canc Inst, Div Med Oncol, Salt Lake City, UT USA
[3] City Hope Comprehens Canc Ctr, Dept Radiat Oncol, Duarte, CA USA
[4] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, Mexico
[5] Univ Calif San Francisco, San Francisco, CA USA
[6] UNLV, Kerk Kerkorian Sch Med, Las Vegas, NV USA
[7] Translat Genom Res Inst, Integrated Canc Genom Div, Phoenix, AZ USA
[8] City Hope Comprehens Canc Ctr, 1500 East Duarte Rd, Duarte, CA 91010 USA
来源
EUROPEAN UROLOGY ONCOLOGY | 2023年 / 6卷 / 04期
关键词
Genomic sequencing; Transcriptomic sequencing; Gene Set Enrichment Analysis; Metastatic renal cell carcinoma; Stereotactic body radiation; therapy; Reactive oxygen species pathway;
D O I
10.1016/j.euo.2022.11.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Stereotactic body radiation therapy (SBRT) has been shown to be safe and effective for delaying systemic treatment change among patients with metastatic renal cell carcinoma (mRCC). In this study, we sought to assess the genomic signatures of patients with mRCC who underwent SBRT for oligoprogression. A total of 30 patients with oligoprogressive disease were identified, the majority of whom had clear cell renal cell carcinoma (83.3%) and were receiving first-line treatment (53.3%). Genomic and transcriptomic sequencing were available in 20 and 16 patients, respectively. Duration of systemic treatment (DOT) was categorized as that prior (DOT[P]) and subsequent (DOT[S]) to radiation treatment. The median DOT(P) and DOT(S) were 15.1 and 18.3 mo, respectively, with a median DOT(S)/DOT(P) ratio of 1.4. Patients who had a DOT (S)/DOT(P) ratio of >1 had increased expression in pathways related to cell proliferation and development. In contrast, among patients with a ratio of <1, the reactive oxygen species pathway was enriched. This study highlights the potential role of genomics and transcriptomics to refine radiation treatment selection in patients with mRCC. Patient summary: In this study, we looked at mutations and genomic expressions among kidney cancer patients who responded better to stereotactic body radiotherapy. We found that enriched expression of certain pathways might play a role in response to radiotherapy.& COPY; 2022 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:447 / 450
页数:4
相关论文
共 50 条
  • [31] Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma
    Wang, Yi-Jun
    Han, Ting-Ting
    Xue, Jun-Xia
    Chang, Dong-Shu
    Li, Hong-Qi
    Li, Ping
    Wang, Ji-Dong
    Wang, Ying-Jie
    Xia, Ting-Yi
    RADIOLOGIA MEDICA, 2014, 119 (11): : 878 - 883
  • [32] A Multinational Report on Technical Factors of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma
    Siva, S.
    Ellis, R. J., III
    Ponsky, L.
    Teh, B. S.
    Mahadevan, A.
    Muacevic, A.
    Onishi, H.
    Wersall, P.
    Nomiya, T.
    Lo, S. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E577 - E578
  • [33] Stereotactic Body Radiation Therapy for Oligometastatic Renal Cell Carcinoma or Melanoma: Prognostic Factors and Outcomes
    Grossman, C. E.
    Okunieff, P.
    Brasacchio, R. A.
    Katz, A. W.
    Singh, D. P.
    Usuki, K. Y.
    Chen, Y.
    Milano, M. T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E202 - E202
  • [34] When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy
    Miccio, Joseph
    Johung, Kimberly
    ONCOLOGY-NEW YORK, 2019, 33 (05): : 167 - +
  • [35] Stereotactic gamma-ray body radiation therapy for asynchronous bilateral renal cell carcinoma
    Yi-Jun Wang
    Ting-Ting Han
    Jun-Xia Xue
    Dong-Shu Chang
    Hong-Qi Li
    Ping Li
    Ji-Dong Wang
    Ying-Jie Wang
    Ting-Yi Xia
    La radiologia medica, 2014, 119 : 878 - 883
  • [36] A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy"
    Ceresoli, Giovanni L.
    Ghirardelli, Paolo
    Franceschini, Davide
    Scorsetti, Marta
    Vavassori, Vittorio
    LUNG CANCER, 2021, 157 : 165 - 166
  • [37] RENAL CELL CARCINOMA IS NOT RADIO-RESISTANT: THE SAFETY AND EFFICACY OF STEREOTACTIC BODY RADIATION THERAPY FOR PRIMARY LESION OF RENAL CELL CARCINOMA
    Nakagomi, Hiroshi
    Kamiyama, Manabu
    Komiyama, Takafumi
    Marino, Kan
    Aoki, Shinnichi
    Maehata, Yoshiyasu
    Sawada, Norifumi
    Mitsui, Takahiko
    Onishi, Hiroshi
    Takeda, Masayuki
    JOURNAL OF UROLOGY, 2019, 201 (04): : E917 - E917
  • [38] Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
    Velec, Michael
    Haddad, Carol R.
    Craig, Tim
    Wang, Lisa
    Lindsay, Patricia
    Brierley, James
    Brade, Anthony
    Ringash, Jolie
    Wong, Rebecca
    Kim, John
    Dawson, Laura A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (05): : 939 - 946
  • [39] Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
    Velec, M.
    Craig, T.
    Wang, L.
    Russo, M.
    Lindsay, P. E.
    Haddad, C. R.
    Kim, J. J.
    Dawson, L. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E175 - E175
  • [40] Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
    Liu, Yang
    Zhang, Zhiling
    Han, Hui
    Guo, Shengjie
    Liu, Zhuowei
    Liu, Mengzhong
    Zhou, Fangjian
    Dong, Pei
    He, Liru
    FRONTIERS IN ONCOLOGY, 2021, 11